GLP-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-24. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Rho factor A protein cofactor involved in signaling the termination of transcription in bacteria. Rho factor recognizes and binds a C-rich/G-poor terminator sequence in the nascent RNA transcript, which promotes dissociation of the transcriptional complex and release of the transcript from the DNA template. Other mechanisms of termination which do not require Rho factor also exist.
=== Astrophysics === MHD applies to astrophysics, including stars, the interplanetary medium (space between the planets), the interstellar medium (space between the stars), and jets. Most astrophysical systems are not in local thermal equilibrium and therefore require an additional kinematic treatment to describe all the phenomena within the system (see Astrophysical plasma). Sunspots are caused by the Sun's magnetic fields, as Joseph Larmor theorized in 1919. The solar wind, predicted by Eugene Parker, is also described by MHD. The differential solar rotation may be the long-term effect of magnetic drag at the Sun's poles, an MHD phenomenon resulting from the Parker spiral shape of the Sun's extended magnetic field. Previously, theories describing the formation of the Sun and planets could not explain how the Sun contains 99.87% of the mass, yet only 0.54% of the angular momentum, in the Solar System. In a closed system, such as the cloud of gas and dust from which the Sun formed, mass and angular momentum are both conserved. That conservation would imply that, as the mass concentrated at the center of the cloud to form the Sun, it would spin faster, much like a skater pulling in their arms. The high rotational speed predicted by early theories would have flung the proto-Sun apart before it could form. However, magnetohydrodynamic effects transfer the Sun's angular momentum to the outer solar system, slowing its rotation. Breakdown of ideal MHD, in the form of magnetic reconnection, is thought to be the likely cause of solar flares.
=== 11 June === Russia claimed to have taken the villages of Synkivka, 120 kilometers east of Kharkiv, and Myasozharivka in Luhansk Oblast. The claim over the capture of Synkivka was not supported by war analysts like DeepStateMap.Live, which continued to depict Russian attack vectors to the north and east of the village, but no capture. A Ukrainian Switchblade, believed to be a 600 or improved model, struck a Russian Buk missile launcher in Sarabash, Donetsk Oblast. Ukraine formally established the Unmanned Systems Forces, a branch of the Ukrainian military presiding over the force's drone operations. The US State Department lifted its ban on providing weapons and training to the Azov Regiment after clearing them on charges of human rights abuses in a review. The New York Times reported that the Russian army was recruiting female prisoners to serve in Ukraine. During a press conference in Germany with President Zelenskyy, German Defence Minister Boris Pistorius announced that Germany and its allies had collected some 100 Patriot missiles for delivery. Pistorius further announced that Germany would also donate a third Patriot battery, IRIS-T missiles and more Gepard anti-aircraft guns in a package worth some five hundred million euros.
Though clinical scientists have existed in the UK National Health Service for ≈60 years, the introduction of formally-trained and accredited consultant-level clinical scientists is relatively new, and was introduced as part of the new Modernizing Scientific Careers framework developed in 2008. Consultant clinical scientists are expected to provide expert scientific and clinical leadership alongside and, at the same level as, medical consultant colleagues. While specialists in healthcare science will follow protocols, procedures and clinical guidelines, consultant clinical scientists will help shape future guidelines and the implementation of new and emerging technologies to help advance patient care. In the United Kingdom, healthcare scientists including clinical scientists may intervene throughout entire care pathways from diagnostic tests to therapeutic treatments and rehabilitation. Although this workforce comprises approximately 5% of the healthcare workforce in the UK, their work underpins 80% of all diagnoses and clinical decisions.
Sources: en.wikipedia.org
There are several pressure-lowering medication groups that could be used in lowering the IOP, usually eyedrops. The choice of medication usually depends on the dose, duration, and side effects of each medication. However, in general, prostaglandin analogues are the first-line treatment for glaucoma. Prostaglandin analogues, such as latanoprost, bimatoprost, and travoprost, reduce the IOP by increasing the aqueous fluid outflow through the draining angle. It is usually prescribed once daily at night. The systemic side effects of this class are minimal. However, they can cause local side effects, including redness of the conjunctiva, a change in the iris color, and eyelash elongation. Several other classes of medications could be used as a second-line in case of treatment failure or presence of contraindications to prostaglandin analogues. These include:
==== Wars with Assyria and Babylonia ==== The Kingdom of Israel was conquered by the Neo-Assyrian Empire around 720 BCE. The records of Sargon II of Assyria indicate that he deported part of the population to Assyria. Some Israelites migrated to the southern kingdom of Judah, while those that remained in Samaria, concentrated mainly around Mount Gerizim, developed a new ethnic identity as Samaritans. Foreign groups were also settled by the Assyrians in the territories of the conquered kingdom. Research indicates that only a portion of the surviving Israelite population intermarried with Mesopotamian settlers. In their native Samaritan Hebrew, the Samaritans identify as "Israel", "B'nai Israel" or "Shamerim/Shomerim" (i.e. "Guardians/Keepers/Watchers"). Despite this, belief in the Ten Lost Tribes of Israel emerged because of the heavy assimilation faced by Samarian deportees. Towards the end of the same century, the Neo-Babylonian Empire emerged victorious over the Assyrians, leading to Judah's subjugation as a vassal state. In the early 6th century BC, a series of revolts in Judah prompted the Babylonian king Nebuchadnezzar II to lay siege to and destroy Jerusalem along with the First Temple, marking the kingdom's demise. Subsequently, a segment of the Judahite populace was exiled to Babylon in several waves. Judeans were progenitors of the Jewish people, who practised Second Temple Judaism during the Second Temple period.
=== Other === It was approved for treating ankylosing spondylitis, psoriatic arthritis, psoriasis, rheumatoid arthritis. Infliximab is also prescribed (out of indication) for the treatment of Behçet's disease. Infliximab is the most frequently used biological agent in treating relapsing polychondritis. Half of the patients saw benefit from this treatment, and a few other patients experienced infections that in some cases lead to death. There have been numerous case reports of the efficacy of infliximab in various inflammatory skin conditions diseases; the FDA approved infliximab for chronic severe plaque psoriasis in adults in September 2006. Infliximab has been used off-label in treating refractory sarcoidosis, where other treatments have not been effective. Infliximab has been tested in chronic obstructive pulmonary disease (COPD) but there was no evidence of benefit with the possibility of harm. Infliximab is indicated for steroid refractory checkpoint inhibitor induced colitis, at a dose of 5 to 10 mg/kg. Infliximab has been found to be a safe alternative treatment to a second dose of IVIG for Kawasaki Disease resistant to initial IVIG therapy, showing better outcomes in fever resolution and fewer severe adverse effects such as hemolytic anemia.
Sources: en.wikipedia.org
== A scientific home in Pittsburgh == In a few short years, the Dean of the School of Medicine, himself a professor of Biochemistry, invited Hofmann to become Chairman of the Department. From the moment he took the position of Chairman of Biochemistry, it became clear that although he would always be a son of Switzerland, the United States offered him career opportunities he could never hope for in a small country like Switzerland. The US was to become his permanent home. The burgeoning field of peptide chemistry became his scientific focus and, in his own words, he fell in love with a molecule that was known to stimulate the adrenal cortex to produce the very steroids that had so fascinated him in Reichstein's laboratory. That molecule, not yet isolated, was ACTH and the love affair was lifelong. Despite detours into other areas, he kept returning to ACTH. In the last years before his death, he was developing methods to isolate the ACTH receptor.
=== Research limitations === Inconsistencies in dosing, purity, and concomitant drug use makes evaluating the effects of mitragynine in humans difficult. Conversely, animal studies control for such variability, but offer limited translatable information relevant to humans. Experimental limitations aside, mitragynine has been found to interact with a variety of receptors, although the nature and extent of receptor interactions has yet to be fully characterized. Additionally, the toxicity of mitragynine and associated kratom alkaloids has yet to be fully determined in humans, nor has the risk of overdose. More studies are necessary to assess safety and potential therapeutic utility.
=== Antifungal === One of the main uses of amphotericin B is treating a wide range of systemic fungal infections. Due to its extensive side effects, it is often reserved for severe infections in critically ill or immunocompromised patients. It is considered first line therapy for invasive mucormycosis infections, cryptococcal meningitis, and certain aspergillus and candidal infections. It has been a highly effective drug for over fifty years in large part because it has a low incidence of drug resistance in the pathogens it treats. This is because amphotericin B resistance requires sacrifices on the part of the pathogen that make it susceptible to the host environment, and too weak to cause infection.
=== Industrial wastewater treatment === Manufacturers of antimicrobials need to improve the treatment of their wastewater (by using industrial wastewater treatment processes) to reduce the release of residues into the environment.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.